Table 3.
Incidence of molecular marker immunopositivity in OSCC (Cohort III)
| Biomarker | Total patients (n = 43) | Lymph node-positive (n = 16) | Lymph node-negative (n = 27) |
|---|---|---|---|
| AZGP1 cytoplasmic |
31 (72%) |
12 (75%) |
19 (70%) |
| AZGP1 nuclear |
25 (58%) |
11 (69%) |
14 (52%) |
| BTG2 |
16 (37%) |
7 (44%) |
9 (33%) |
| CBX2 |
33 (77%) |
15 (94%) |
18 (67%) |
| CNTNAP2 |
6 (14%) |
4 (25%) |
2 (7%) |
| NME5 |
12 (28%) |
6 (38%) |
6 (22%) |
| S100A8 |
11 (26%) |
3 (19%) |
8 (30%) |
| SCUBE2 |
12 (28%) |
1 (6%) |
11 (41%) |
| SERPINA11 |
17 (40%) |
7 (44%) |
10 (37%) |
| STC2 |
20 (47%) |
7 (44%) |
13 (48%) |
| STK32B |
15 (35%) |
4 (25%) |
11 (41%) |
| SUSD3 |
25 (58%) |
9 (56%) |
16 (59%) |
| UBE2C |
8 (19%) |
3 (19%) |
5 (19%) |
| WHSC1L1 | 37 (86%) | 14 (88%) | 23 (85%) |